How should Olaparib be dosed, monitored, and dose‑adjusted in patients with BRCA‑mutated ovarian, breast, pancreatic, or prostate cancer?

Olaparib Dosing, Monitoring, and Dose Adjustment in BRCA-Mutated Cancers

Olaparib should be dosed at 300 mg orally twice daily using the tablet formulation for maintenance therapy in BRCA-mutated ovarian, breast, pancreatic, and prostate cancers, with dose reductions to 250 mg twice daily or 200 mg twice daily as needed for toxicity management. 1, 2

Standard Dosing by Indication

Ovarian Cancer

• Standard dose: 300 mg twice daily (two 150 mg tablets) for maintenance therapy in patients with germline or somatic BRCA mutations who have responded to platinum-based chemotherapy 3, 4
• Treatment setting: Approved for first-line maintenance (BRCA-mutated disease) and second-line maintenance (limited to BRCA-mutated disease only per FDA restriction) 3
• Duration: Continue until disease progression or unacceptable toxicity 4

Prostate Cancer

• Standard dose: 300 mg twice daily for metastatic castration-resistant prostate cancer (mCRPC) with deleterious or suspected deleterious germline or somatic HRR mutations 5
• Eligible genes: BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L 5
• Prior therapy requirement: Must have received prior enzalutamide or abiraterone; prior taxane therapy not required 5
• Category 1 recommendation for patients with HRR mutations regardless of prior docetaxel 5

Pancreatic Cancer

• Standard dose: 300 mg twice daily as maintenance therapy for germline BRCA1/2-mutated metastatic pancreatic cancer 6
• Eligibility: Disease must not have progressed during first-line platinum-based chemotherapy 6
• Efficacy: Median progression-free survival 7.4 months versus 3.8 months with placebo (HR 0.53, P=0.004) 6

Breast Cancer

• Standard dose: 300 mg twice daily for HER2-negative metastatic breast cancer with germline or somatic BRCA mutations 2, 7
• Treatment line: After prior chemotherapy in neoadjuvant, adjuvant, or metastatic setting 2

Critical Formulation Distinction

The capsule and tablet formulations are NOT interchangeable due to different bioavailability 2

• Capsule formulation: 400 mg twice daily (eight 50 mg capsules) - older formulation 2
• Tablet formulation: 300 mg twice daily (two 150 mg tablets) - current approved formulation 2, 4
• Never substitute one formulation for another without adjusting dose 2

Dose Modifications for Adverse Events

Common Toxicities Requiring Management

The most frequent adverse events are nausea, fatigue, vomiting, anemia, and diarrhea, typically mild to moderate and transient 8, 9

Hematologic Toxicity

• Anemia: Most common grade ≥3 adverse event (13.6% in OPINION trial) 10
• Management approach: Dose interruption followed by dose reduction if recurrent 9
• Thrombocytopenia and neutropenia: Monitor complete blood counts regularly 3

Dose Reduction Schedule

• First reduction: 250 mg twice daily 9
• Second reduction: 200 mg twice daily 9
• Discontinuation: If toxicity persists at 200 mg twice daily 9

Gastrointestinal Toxicity

• Nausea/vomiting: Implement prophylactic antiemetics early; most cases are mild to moderate 9
• Diarrhea: Supportive management with antidiarrheals 8
• Dose interruption may be required for severe symptoms, followed by dose reduction if recurrent 9

Monitoring Requirements

Baseline Assessment

• Genetic testing: Confirm BRCA1/2 mutation status using validated companion diagnostics 4
  • BRACAnalysis CDx for germline BRCA mutations 4
  • FoundationOne CDx for tissue-based BRCA mutations 4
  • Myriad myChoice CDx for HRD status (when using with bevacizumab) 4

Ongoing Monitoring

• Complete blood counts: Regular monitoring for anemia, thrombocytopenia, neutropenia 3, 10
• Renal function: Monitor creatinine elevation 5
• Pulmonary symptoms: Assess for cough, dyspnea, and drug-induced pneumonitis 5
• Thromboembolic events: Monitor for pulmonary emboli and other thromboembolic complications 5

Long-term Safety Concerns

• Myelodysplastic syndrome/acute myeloid leukemia: Theoretical risk requiring long-term vigilance 5, 10
• In OPINION trial: Only 2 cases of MDS reported among 279 patients 10

Drug Interactions

Avoid concurrent use with strong or moderate CYP3A inducers or inhibitors, as these may significantly alter olaparib plasma concentrations 8

Biomarker-Specific Efficacy Considerations

Highest Efficacy: BRCA1/2 Mutations

• Germline BRCA-mutated ovarian cancer: 18-month OS rate 86.4% 11
• Somatic BRCA-mutated ovarian cancer: 18-month OS rate 88.0% 11
• BRCA2-mutated prostate cancer: OS benefit with HR 0.59 5, 12

Moderate Efficacy: HRD-Positive Non-BRCA

• HRD-positive non-BRCA ovarian cancer: 18-month OS rate 78.6% 11
• 24-month OS rate: 72.0% in HRD-positive excluding sBRCAm 10

Lower Efficacy: HRD-Negative

• HRD-negative ovarian cancer: 18-month OS rate 59.6% 11
• ATM-mutated prostate cancer: OS HR 0.93 (no significant benefit) 5

Critical Pitfalls to Avoid

• Do not use PARP inhibitors in second-line maintenance for non-BRCA-mutated ovarian cancer - FDA restricted indications to BRCA-mutated disease only after safety concerns 3
• Do not assume all HRR gene mutations respond equally - efficacy in prostate cancer is driven primarily by BRCA1/2 mutations, with heterogeneous responses in other genes 5
• Do not delay dose modifications - early intervention with dose interruption and reduction maintains treatment adherence 9
• Do not use in platinum-resistant disease as monotherapy - associated with worse overall survival in ARIEL-4 trial 3
• Patients with CDK12 mutations do not respond well to PARP inhibitors and should be considered for alternative therapies 5